Acceleration and Augmentation of Antidepressants With Lithium for Depressive Disorders: Two Meta-Analyses of Randomized, Placebo-Controlled Trials
The DOI matches its Crossref record.
Abstract
OBJECTIVE: The delayed onset of therapeutic response and the high number of nonresponders to antidepressants remain major clinical problems in depressive disorders. Among the strategies to overcome both dilemmas, the additional treatment with lithium has been suggested as a viable method. The authors determined in 2 separate meta-analyses the efficacy of lithium in accelerating and in augmenting clinical response in patients with depression. STUDY SELECTION AND DATA SOURCES: Two meta-analyses of randomized, double-blind, placebo-controlled trials including subjects with unipolar or bipolar disorder, depressive phase, assessed the concomitant administration of lithium and antidepressant to accelerate or augment clinical response in the acute treatment phase of depression. Data were obtained from searching the following databases: MEDLINE (1966 to July 2006), EMBASE (1989 to July 2006), and The Cochrane Central Register of Controlled Trials (The Cochrane Library 2006, Issue 3). For the accelerating meta-analysis, subject headings including depressive disorder, bipolar disorder, antidepressive agents, and lithium and text words such as depress*, lithium, and antidepress* were used. For the augmentation meta-analysis, subject headings included depressive disorder, bipolar disorder, anti-depressive agents, lithium, drug therapy, and combination, and text words included augment*, refract*, and resistant. Outcomes investigated included response rates and depression scale rates. DATA SYNTHESIS: Five acceleration studies (231 participants) adding lithium to tricyclics and tetracyclics and 10 augmentation studies (269 participants) adding lithium to various antidepressants including selective serotonin reuptake inhibitors were incorporated. In the acceleration meta-analysis, a statistical trend in favor of lithium was found (standardized mean difference of -0.43, 95% CI = -0.93 to 0.07). In the augmentation meta-analysis, lithium was significantly more effective than placebo (odds ratio = 3.11, 95% CI = 1.80 to 5.37). CONCLUSION: There is firm evidence for lithium as an effective augmentation strategy but only modest evidence for lithium to accelerate response to antidepressants in patients with depressive disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The extant evidence supporting lithium and thyroid hormone largely refers to their combination with TCAs and MAOIs in patients with partial response to these agents.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [277]
Citations
Cites
Still being checked.
Cited by
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Lithium, a widely supported and used augmentation agent, is found to be more effective than placebo in augmentation of TCAs, SSRIs and other antidepressants (Bauer et al., 2000; Crossley and Bauer, 2007).”
BackgroundMcIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“A meta-analysis including 10 prospective studies provided fi rm evidence that lithium augmentation is superior to placebo in unipolar major depression, with response rates on average of 41.2% in the lithium group and 14.4% in the placebo group (Crossley and Bauer 2007).”
MethodInfluentialSelf-citationNelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Self-citationLam, R. W., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901206 · Cited by 438
Connolly, K. R., & Thase, M. E. (2011) · Drugs · doi:10.2165/11587620-000000000-00000 · Cited by 462
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“24 Less evidence exists for augmentation of current fi rst-line antidepressant pharmacotherapy (from the selective serotonin reuptake inhibitor class).”
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“The most recent meta-analysis (10 RCTs, N=269 participants) found it significantly superior to placebo in augmentation of antidepressants, including TCAs and SSRIs (Crossley and Bauer, 2007).”
BackgroundTherapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
“Lithium is frequently used as an augmentation strategy in refractory unipolar depression (Crossley and Bauer 2007).”
BackgroundBaldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics
Alda, M. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.4 · Cited by 315
Lenze, E. J., Mulsant, B. H., Blumberger, D. M., Karp, J. F., Newcomer, J. W., Anderson, S. J., Dew, M. A., Butters, M. A., Stack, J. A., Begley, A. E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00308-6 · Cited by 283
McAllister-Williams, R. H., Arango, C., Blier, P., Demyttenaere, K., Falkai, P., Gorwood, P., Hopwood, M., Javed, A., Kasper, S., Malhi, G. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.023 · Cited by 278
Therapeutic Options for Treatment-Resistant Depression
Shelton, R. C., Osuntokun, O., Heinloth, A. N., & Corya, S. A. (2010) · CNS Drugs · doi:10.2165/11530280-000000000-00000 · Cited by 205
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
Self-citationKaster, T. S., Daskalakis, Z. J., Noda, Y., Knyahnytska, Y., Downar, J., Rajji, T. K., Levkovitz, Y., Zangen, A., Butters, M. A., Mulsant, B. H., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0121-x · Cited by 174
Essential elements in depression and anxiety. Part I
Młyniec, K., Davies, C. L., de Agüero Sánchez, I. G., Pytka, K., Budziszewska, B., & Nowak, G. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.03.001 · Cited by 170
Jakobsson, E., Argüello‐Miranda, O., Chiu, S.-W., Fazal, Z., Kruczek, J., Núñez-Corrales, S., Pandit, S. A., & Pritchet, L. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9998-2 · Cited by 181
Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.01.015 · Cited by 161
Grunze, H. (2011) · FOCUS: The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.9.4.500 · Cited by 149
Nelson, J. C., Baumann, P., Delucchi, K., Joffe, R. T., & Katona, C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.053 · Cited by 157
Schefft, C., Kilarski, L. L., Bschor, T., & Köhler, S. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.004 · Cited by 137
Evidence-based pharmacotherapy of treatment-resistant unipolar depression
Dold, M., & Kasper, S. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1248852 · Cited by 118
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Role of Lithium Augmentation in the Management of Major Depressive Disorder
Bauer, M., Adli, M., Ricken, R., Severus, E., & Pilhatsch, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0152-8 · Cited by 140
Self-citationBauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., Schmid, R., & Lewitzka, U. (2010) · Neuropsychobiology · doi:10.1159/000314308 · Cited by 121
Self-citationAntidepressants plus benzodiazepines for adults with major depression
Ogawa, Y., Takeshima, N., Hayasaka, Y., Tajika, A., Watanabe, N., Streiner, D., & Furukawa, T. A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001026.pub2 · Cited by 110
Bennabi, D., Charpeaud, T., Yrondi, A., Genty, J.-B., Destouches, S., Lancrenon, S., Alaïli, N., Bellivier, F., Bougerol, T., Camus, V., et al. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2237-x · Cited by 100
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 115
Adli, M., Hollinde, D. L., Stamm, T. J., Wiethoff, K., Tsahuridu, M., Kirchheiner, J., Heinz, A., & Bauer, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.023 · Cited by 111
Self-citationTherapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102
Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression
Lenze, E. J., Mulsant, B. H., Roose, S. P., Lavretsky, H., Reynolds, C. F., Blumberger, D. M., Brown, P. J., Cristancho, P., Flint, A. J., Gebara, M. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204462 · Cited by 110
Bauer, M., Pfennig, A., Linden, M., Smolka, M. N., Neu, P., & Adli, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ac4839 · Cited by 94
Self-citationLithium in the treatment of major depressive disorder
Bschor, T. (2014) · Drugs · doi:10.1007/s40265-014-0220-x · Cited by 94
“4) and a number needed to treat (NNT) of five [25, 26].”
BackgroundPharmacologic approaches to treatment resistant depression: Evidences and personal experience
Tundo, A., Filippis, R. D., & Proietti, L. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i3.330 · Cited by 91
Lithium treatment for unipolar major depressive disorder: Systematic review
Undurraga, J. P., Sim, K., Tondo, L., Gorodischer, A., de Azúa, E. R., Tay, K. H., Tan, D. S. P., & Baldessarini, R. J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822161 · Cited by 94
Millan, M. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001496 · Cited by 79
Treatment-Resistant Depression in Older Adults
Steffens, D. C. (2024) · New England Journal of Medicine · doi:10.1056/nejmcp2305428 · Cited by 90
Augmentation strategies for treatment-resistant depression
Carvalho, A. F., Machado, J. R., & Cavalcante, J. L. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32831be9ef · Cited by 78
Bschor, T., & Baethge, C. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01458.x · Cited by 75
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
“The guidance from BAP regarding modafinil augmentation is limited, as they stated that there is only preliminary evidence for its use over the short term and cited the same meta-analysis of 4 MDD RCTs as CANMAT (Goss et al., 2013).”
BackgroundMethodInfluentialEdwards, S., Hamilton, V, Nherera, L., & Trevor, N. (2013) · Health Technology Assessment · doi:10.3310/hta17540 · Cited by 71
Treatment‐resistant bipolar depression: towards a new definition
Pacchiarotti, I., Mazzarini, L., Colom, F., Sanchez‐Moreno, J., Girardi, P., Kotzalidis, G. D., & Vieta, E. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01471.x · Cited by 74
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era
Philip, N. S., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003614781 · Cited by 70
Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014977 · Cited by 73
The hidden third: improving outcome in treatment-resistant depression
Schlaepfer, T. E., Ågren, H., Monteleone, P., Gasto, C., Pitchot, W., Rouillon, F., Nutt, D. J., & Kasper, S. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111431748 · Cited by 74
Abou-Saleh, M. T., Müller-Oerlinghausen, B., & Coppen, A. J. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0080-x · Cited by 74
“Meta-analysis by Crossley and Bauer (2007) included 10 placebo-controlled trials showing that lithium was not only more efficacious than placebo but had a relatively large effect size and number-needed-to-treat of 5.”
MethodAccelerating response to antidepressant treatment in depression: A review and clinical suggestions
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.001 · Cited by 80
Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms
Kurian, B. T., Greer, T. L., & Trivedi, M. H. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.53 · Cited by 73
“A number of agents are currently used clinically for augmenting primary antidepressants, of which lithium and triiodothyronine (T3) are most commonly used as first-line augmenting agents [16–20].”
BackgroundBauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 73
Self-citationAdult hippocampal neurogenesis: Is it the alpha and omega of antidepressant action?
Eliwa, H., Belzung, C., & Surget, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.005 · Cited by 78
Adli, M., Wiethoff, K., Baghai, T. C., Fisher, R., Seemüller, F., Laakmann, G., Brieger, P., Cordes, J., Malevani, J., Laux, G., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx043 · Cited by 71
Self-citationChronic and Treatment Resistant Depression
Bschor, T., Bauer, M., & Adli, M. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0766 · Cited by 67
Self-citationPredictors of lithium response in bipolar disorder
Tighe, S. K., Mahon, P. B., & Potash, J. B. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311399173 · Cited by 78
Augmentation treatment in major depressive disorder: focus on aripiprazole
Berman, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3369 · Cited by 74
Triacetyluridine (TAU) decreases depressive symptoms and increases brain pH in bipolar patients.
Jensen, J. E., Daniels, M., Haws, C., Bolo, N. R., Lyoo, I. K., Yoon, S. J., Cohen, B. M., Stoll, A. L., Rusche, J. R., & Renshaw, P. F. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.3.199 · Cited by 64
Challenging the Negative Perception of Lithium and Optimizing Its Long-Term Administration
RYBAKOWSKI, J. K. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00349 · Cited by 69
Management of Treatment-Resistant Depression
Keitner, G. I., & Mansfield, A. K. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.004 · Cited by 70
A critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Tiihonen, J., Tanskanen, A., Hoti, F., Vattulainen, P., Taipale, H., Mehtälä, J., & Lähteenvuo, M. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30134-7 · Cited by 58
Lithium and cognitive enhancement: leave it or take it?
Tsaltas, E., Kontis, D., Boulougouris, V., & Papadimitriou, G. N. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1311-8 · Cited by 61
Costemale-Lacoste, J.-F., Guilloux, J., & Gaillard, R. (2016) · L Encéphale · doi:10.1016/j.encep.2016.02.003 · Cited by 61
Adler, U. C., Paiva, N. M. P., César, A., Adler, M. S., Molina, A., Padula, A. E. M., & Calil, H. M. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep114 · Cited by 68
Lithium in neuropsychiatry: A 2010 update
RYBAKOWSKI, J. K. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.559274 · Cited by 60
Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
EGF Receptor Inhibition by Erlotinib Increases Aquaporin 2–Mediated Renal Water Reabsorption
Cheung, P. W., Nomura, N., Nair, A. V., Pathomthongtaweechai, N., Ueberdiek, L., Lu, H. A. J., Brown, D., & Bouley, R. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015080903 · Cited by 54
History, background, concepts and current use of comedication and polypharmacy in psychiatry
Möller, H. ‐., Seemüller, F., Schennach-Wolff, R., Stübner, S., Rüther, E., & Grohmann, R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000837 · Cited by 56
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 57
Self-citationGuidelines for the diagnosis and treatment of depressive disorders in China: The second edition
Feng, Y., Xiao, L., Wang, W., Ungvari, G. S., Ng, C. H., Wang, G., & Xiang, Y. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.104 · Cited by 51
Yoshimura, R., Ikenouchi, A., Hori, H., Umene‐Nakano, W., Katsuki, A., Hayashi, K., Ueda, N., & Nakamura, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.003 · Cited by 54
Bauer, M., Blumentritt, H., Finke, R., Schlattmann, P., Adli, M., Baethge, C., Bschor, T., Müller-Oerlinghausen, B., & Berghöfer, A. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.033 · Cited by 47
Self-citationOptimizing the management of depression: primary care experience
Cameron, C., Habert, J., Anand, L., & Furtado, M. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70005-8 · Cited by 59
Hamoda, H. M., & Osser, D. N. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802277904 · Cited by 47
Tachyphylaxis in major depressive disorder: A review of the current state of research
Kinrys, G., Gold, A. K., Pisano, V. D., Freeman, M. P., Papakostas, G. I., Mischoulon, D., Nierenberg, A. A., & Fava, M. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.357 · Cited by 45
Clinical Update on Nursing Home Medicine: 2009
Messinger‐Rapport, B. J., Thomas, D. R., Gammack, J. K., & Morley, J. E. (2009) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2009.08.001 · Cited by 53
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., van Asselt, A. D. I., Touw, D. J., aan het Rot, M., & Schoevers, R. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2359-1 · Cited by 39
Current Nosology of Treatment Resistant Depression: A Controversy Resistant to Revision
Fornaro, M., & Giosuè, P. (2010) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901006010020 · Cited by 42
Polypharmacy with antidepressants in children and adolescents
Díaz‐Caneja, C. M., Espliego, A., Parellada, M., Arango, C., & Moreno, C. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001265 · Cited by 46
Lithium in bipolar and other affective disorders: prescribing practice in the UK
Paton, C., Barnes, T. R. E., Shingleton‐Smith, A., McAllister-Williams, H., Kirkbride, J. B., Jones, P. B., & McIntyre, S. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110367728 · Cited by 45
Abbasi, N., Mirabzadeh, Y., Khesali, G., Ebrahimkhani, Z., Karimi, H., & Vaseghi, S. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06566-0 · Cited by 43
Evidenzbasierte Therapie der Depression: Die S3-Leitlinie unipolare Depression
Härter, M. C., Klesse, C., Bermejo, I., Bschor, T., Gensichen, J., Harfst, T., Hautzinger, M., Kolada, C., Kopp, I., Kühner, C., et al. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3084-7 · Cited by 46
The Neglected Role of Psychotherapy for Treatment-Resistant Depression
Markowitz, J. C., Wright, J. H., Peeters, F., Thase, M. E., Kocsis, J. H., & Sudak, D. M. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21050535 · Cited by 41
Pharmacological management of unipolar depression
Malhi, G. S., Hitching, R., Berk, M., Boyce, P., Porter, R., & Fritz, K. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12122 · Cited by 42
Garakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328301a74c · Cited by 39
Lithium: Current state of the art and future directions
Gitlin, M., & Bauer, M. (2024) · International Journal of Bipolar Disorders · doi:10.1186/s40345-024-00362-7 · Cited by 38
Self-citationPredictors of efficacy in lithium augmentation for treatment-resistant depression
Sugawara, H., Sakamoto, K., Harada, T., & Ishigooka, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.025 · Cited by 38
California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines
Stahl, S. M., Morrissette, D. A., Cummings, M. A., Azizian, A., Bader, S. M., Broderick, C., Dardashti, L. J., Delgado, D., Meyer, J. M., O’Day, J., et al. (2014) · CNS Spectrums · doi:10.1017/s1092852914000376 · Cited by 40
Köhler, S., Wiethoff, K., Ricken, R., Stamm, T. J., Baghai, T. C., Fisher, R., Seemüller, F., Brieger, P., Cordes, J., Malevani, J., et al. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.10.059 · Cited by 37
Self-citationLithium: A classic drug—Frequently discussed, but, sadly, seldom prescribed!
Zivanović, O. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417695889 · Cited by 38
An algorithm for the pharmacological treatment of depression
Spijker, J., & Nolen, W. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01492.x · Cited by 35
Is lithium monitoring NICE? Lithium monitoring in a UK secondary care setting
Nikolova, V. L., Pattanaseri, K., Hidalgo‐Mazzei, D., Taylor, D. M., & Young, A. H. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760663 · Cited by 33
Lithium – past, present, future
RYBAKOWSKI, J. K. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1775855 · Cited by 34
Kast, R. E. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705872 · Cited by 33
Metadata
- Authors
- Crossley, N. A., & Bauer, M.
- Affiliations
- Charité – Universitätsmedizin Berlin (DE)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-06-15
- Volume
- 68
- Issue
- 06
- Pages
- 935-940
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2010317561
- Cited by
- 246
- References
- 0
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 4 · 2022: 11 · 2021: 5 · 2020: 13 · 2019: 11 · 2018: 12 · 2017: 12 · 2016: 9 · 2015: 9 · 2014: 19 · 2013: 20 · 2012: 16
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- lithium, antidepressant augmentation, depression, bipolar disorder, treatment-resistant depression, tricyclic antidepressants, selective serotonin reuptake inhibitors, tetracyclic antidepressants, response rate
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Drug Interactions, Drug Therapy, Combination, Humans, Randomized Controlled Trials as Topic, Lithium Carbonate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.